5
Clinical Trials associated with 13-valent pneumococcal conjugate vaccine(Fosun Adgenvax Biotechonology)13价肺炎球菌结合疫苗(多价结合体)III 期(2-3 月龄)临床试验的免疫持久性补充临床试验
[Translation] Supplemental clinical trial of immune persistence in Phase III (2-3 months) clinical trial of 13-valent pneumococcal conjugate vaccine (multivalent conjugate)
评价2月龄(最小满6 周龄)和3月龄婴幼儿完成基础免疫3剂和加强免疫1剂13价肺炎球菌结合疫苗接种后的免疫持久性。
[Translation] To evaluate the persistence of immunity in infants aged 2 months (minimum 6 weeks) and 3 months after completing 3 doses of primary immunization and 1 dose of booster immunization with 13-valent pneumococcal conjugate vaccine.
评价13价肺炎球菌结合疫苗(多价结合体)在2月龄(最小满6周龄)和3月龄婴幼儿中的免疫原性和安全性的III期临床试验
[Translation] Phase III clinical trial to evaluate the immunogenicity and safety of 13-valent pneumococcal conjugate vaccine (multivalent conjugate) in infants aged 2 months (minimum 6 weeks) and 3 months
1、与对照苗比较,评价试验疫苗在2月龄(最小满6周龄)和3月龄婴幼儿中按照相应免疫程序接种后的免疫原性;
2、评价试验疫苗在2月龄(最小满6周龄)和3月龄人群中接种后的安全性。
[Translation] 1. Compare with the control vaccine, evaluate the immunogenicity of the test vaccine after vaccination in 2-month-old (minimum 6 weeks old) and 3-month-old infants and young children according to the corresponding immunization schedule;
2. Evaluate the safety of the test vaccine after vaccination in 2-month-old (minimum 6 weeks old) and 3-month-old populations.
Phase III clinical trial to evaluate the immunogenicity and safety of 13-valent pneumococcal conjugate vaccine (multivalent conjugate) in infants aged 2 months (at least 6 weeks) and 3 months
Start Date04 Nov 2022 |
Sponsor / Collaborator- |
100 Clinical Results associated with 13-valent pneumococcal conjugate vaccine(Fosun Adgenvax Biotechonology)
100 Translational Medicine associated with 13-valent pneumococcal conjugate vaccine(Fosun Adgenvax Biotechonology)
100 Patents (Medical) associated with 13-valent pneumococcal conjugate vaccine(Fosun Adgenvax Biotechonology)
100 Deals associated with 13-valent pneumococcal conjugate vaccine(Fosun Adgenvax Biotechonology)